{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T16:41:03Z","timestamp":1792773663631,"version":"4.5.0"},"reference-count":86,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2027,2,1]],"date-time":"2027-02-01T00:00:00Z","timestamp":1801440000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2027,2,1]],"date-time":"2027-02-01T00:00:00Z","timestamp":1801440000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:00:00Z","timestamp":1778716800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82272925"],"award-info":[{"award-number":["82272925"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008233","name":"Shanghai Jiao Tong University School of Medicine","doi-asserted-by":"publisher","award":["20240815"],"award-info":[{"award-number":["20240815"]}],"id":[{"id":"10.13039\/501100008233","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Genes & Diseases"],"published-print":{"date-parts":[[2027,2]]},"DOI":"10.1016\/j.gendis.2026.102245","type":"journal-article","created":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T07:01:06Z","timestamp":1779174066000},"page":"102245","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["In vivo CAR-T for the treatment of autoimmune diseases: Current progress and future directions"],"prefix":"10.1016","volume":"14","author":[{"given":"Yufan","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9151-5146","authenticated-orcid":false,"given":"Yuhang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaochun","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0279-8784","authenticated-orcid":false,"given":"Quanjun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10055","key":"10.1016\/j.gendis.2026.102245_bib1","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1016\/S0140-6736(16)30173-8","article-title":"Rheumatoid arthritis","volume":"388","author":"Smolen","year":"2016","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.gendis.2026.102245_bib2","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1056\/NEJMra1909094","article-title":"Reframing immune-mediated inflammatory diseases through signature cytokine hubs","volume":"385","author":"Schett","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gendis.2026.102245_bib3","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1647066","article-title":"Innovations in immunotherapy for autoimmune diseases: recent breakthroughs and future directions","volume":"16","author":"Alsayb","year":"2025","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.gendis.2026.102245_bib4","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1038\/s41401-023-01207-2","article-title":"Autoimmune diseases: targets, biology, and drug discovery","volume":"45","author":"Li","year":"2024","journal-title":"Acta Pharmacol Sin"},{"issue":"1","key":"10.1016\/j.gendis.2026.102245_bib5","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.cell.2020.03.007","article-title":"Challenges, progress, and prospects of developing therapies to treat autoimmune diseases","volume":"181","author":"Fugger","year":"2020","journal-title":"Cell"},{"issue":"6295","key":"10.1016\/j.gendis.2026.102245_bib6","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1126\/science.aaf6756","article-title":"Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease","volume":"353","author":"Ellebrecht","year":"2016","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.gendis.2026.102245_bib7","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/nrrheum.2011.1","article-title":"Long-lived autoreactive plasma cells drive persistent autoimmune inflammation","volume":"7","author":"Hiepe","year":"2011","journal-title":"Nat Rev Rheumatol"},{"issue":"9","key":"10.1016\/j.gendis.2026.102245_bib8","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.00026-22","article-title":"Persistence of virus-specific antibody after depletion of memory B cells","volume":"96","author":"Langley","year":"2022","journal-title":"J Virol"},{"key":"10.1016\/j.gendis.2026.102245_bib9","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.imlet.2023.06.005","article-title":"Targeting plasma cells in systemic autoimmune rheumatic diseases\u2013promises and pitfalls","volume":"260","author":"Steinmetz","year":"2023","journal-title":"Immunol Lett"},{"issue":"16","key":"10.1016\/j.gendis.2026.102245_bib10","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor-modified T cells for acute lymphoid leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.gendis.2026.102245_bib11","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJMoa1103849","article-title":"Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia","volume":"365","author":"Porter","year":"2011","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.gendis.2026.102245_bib12","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 CAR T-cell therapy in autoimmune disease: a case series with follow-up","volume":"390","author":"M\u00fcller","year":"2024","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.gendis.2026.102245_bib13","doi-asserted-by":"crossref","first-page":"4890","DOI":"10.1016\/j.cell.2024.06.027","article-title":"Allogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosis","volume":"187","author":"Wang","year":"2024","journal-title":"Cell"},{"issue":"10","key":"10.1016\/j.gendis.2026.102245_bib14","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1136\/ard-2024-225785","article-title":"BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial","volume":"83","author":"Wang","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.gendis.2026.102245_bib15","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jaut.2018.08.004","article-title":"Chimeric antigen receptor (CAR) T cells targeting a pathogenic MHC class II: peptide complex modulate the progression of autoimmune diabetes","volume":"96","author":"Zhang","year":"2019","journal-title":"J Autoimmun"},{"key":"10.1016\/j.gendis.2026.102245_bib16","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.addr.2018.12.005","article-title":"Targeting the CD40-CD40L pathway in autoimmune diseases: humoral immunity and beyond","volume":"141","author":"Karnell","year":"2019","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.gendis.2026.102245_bib17","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1490911","article-title":"Logic-gated and contextual control of immunotherapy for solid tumors: contrasting multi-specific T cell engagers and CAR-T cell therapies","volume":"15","author":"Nolan-Stevaux","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.gendis.2026.102245_bib18","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.cytogfr.2025.09.004","article-title":"Designing immunity with cytokines: a logic-based framework for programmable CAR therapies","volume":"86","author":"Upadhyay","year":"2025","journal-title":"Cytokine Growth Factor Rev"},{"issue":"4","key":"10.1016\/j.gendis.2026.102245_bib19","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s11899-021-00635-3","article-title":"Balancing quality, cost, and access during delivery of newer cellular and immunotherapy treatments","volume":"16","author":"Geethakumari","year":"2021","journal-title":"Curr Hematol Malig Rep"},{"key":"10.1016\/j.gendis.2026.102245_bib20","doi-asserted-by":"crossref","DOI":"10.3389\/frtra.2023.1238535","article-title":"Promises and challenges of a decentralized CAR T-cell manufacturing model","volume":"2","author":"Shah","year":"2023","journal-title":"Front Transplant"},{"issue":"1","key":"10.1016\/j.gendis.2026.102245_bib21","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy: assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"10.1016\/j.gendis.2026.102245_bib22","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/s41591-018-0036-4","article-title":"Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells","volume":"24","author":"Norelli","year":"2018","journal-title":"Nat Med"},{"issue":"12","key":"10.1016\/j.gendis.2026.102245_bib23","doi-asserted-by":"crossref","first-page":"6317","DOI":"10.1172\/JCI138416","article-title":"Antigen-specific B cell depletion for precision therapy of mucosal pemphigus vulgaris","volume":"130","author":"Lee","year":"2020","journal-title":"J Clin Invest"},{"issue":"2","key":"10.1016\/j.gendis.2026.102245_bib24","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3390\/biomedicines10020287","article-title":"CAR-T regulatory (CAR-treg) cells: engineering and applications","volume":"10","author":"Arjomandnejad","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.gendis.2026.102245_bib25","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1433432","article-title":"\"Off-the-shelf\" allogeneic chimeric antigen receptor T-cell therapy for B-cell malignancies: current clinical evidence and challenges","volume":"14","author":"Mohty","year":"2024","journal-title":"Front Oncol"},{"issue":"5","key":"10.1016\/j.gendis.2026.102245_bib26","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.tips.2024.03.004","article-title":"Direct in vivo CAR T cell engineering","volume":"45","author":"Short","year":"2024","journal-title":"Trends Pharmacol Sci"},{"issue":"11","key":"10.1016\/j.gendis.2026.102245_bib27","doi-asserted-by":"crossref","DOI":"10.1002\/smll.202304378","article-title":"In vivo mRNA CAR T cell engineering via targeted ionizable lipid nanoparticles with extrahepatic tropism","volume":"20","author":"Billingsley","year":"2024","journal-title":"Small"},{"key":"10.1016\/j.gendis.2026.102245_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2024.105266","article-title":"Advancements and challenges in developing in vivo CAR T cell therapies for cancer treatment","volume":"106","author":"Bui","year":"2024","journal-title":"EBioMedicine"},{"issue":"21","key":"10.1016\/j.gendis.2026.102245_bib29","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1182\/blood-2017-06-793141","article-title":"Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy","volume":"130","author":"Hay","year":"2017","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.gendis.2026.102245_bib30","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"26","key":"10.1016\/j.gendis.2026.102245_bib31","doi-asserted-by":"crossref","first-page":"3321","DOI":"10.1182\/blood-2016-04-703751","article-title":"Toxicities of chimeric antigen receptor T cells: recognition and management","volume":"127","author":"Brudno","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.gendis.2026.102245_bib32","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.3389\/fimmu.2019.02664","article-title":"Mechanisms of relapse after CD19 CAR T-cell therapy for acute lymphoblastic leukemia and its prevention and treatment strategies","volume":"10","author":"Xu","year":"2019","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.gendis.2026.102245_bib33","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1182\/blood-2016-01-694356","article-title":"Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy","volume":"128","author":"Bhoj","year":"2016","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.gendis.2026.102245_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.110766","article-title":"Dynamic spectrum of ectopic lymphoid B cell activation and hypermutation in the RA synovium characterized by NR4A nuclear receptor expression","volume":"39","author":"Meednu","year":"2022","journal-title":"Cell Rep"},{"key":"10.1016\/j.gendis.2026.102245_bib35","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.876339","article-title":"Impact of manufacturing procedures on CAR T cell functionality","volume":"13","author":"Watanabe","year":"2022","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.gendis.2026.102245_bib36","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.26914","article-title":"Hypogammaglobulinemia due to CAR T-cell therapy","volume":"65","author":"Doan","year":"2018","journal-title":"Pediatr Blood Cancer"},{"issue":"11","key":"10.1016\/j.gendis.2026.102245_bib37","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.146743","article-title":"Antibodies against vaccine-preventable infections after CAR-T cell therapy for B cell malignancies","volume":"6","author":"Walti","year":"2021","journal-title":"JCI Insight"},{"issue":"2","key":"10.1016\/j.gendis.2026.102245_bib38","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1182\/bloodadvances.2023011992","article-title":"Early predictive factors of failure in autologous CAR T-cell manufacturing and\/or efficacy in hematologic malignancies","volume":"8","author":"Baguet","year":"2024","journal-title":"Blood Adv"},{"issue":"8","key":"10.1016\/j.gendis.2026.102245_bib39","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/j.jval.2024.04.004","article-title":"Economic evaluations of chimeric antigen receptor T-cell therapies for hematologic and solid malignancies: a systematic review","volume":"27","author":"Thavorn","year":"2024","journal-title":"Value Health"},{"issue":"11","key":"10.1016\/j.gendis.2026.102245_bib40","doi-asserted-by":"crossref","first-page":"5572","DOI":"10.1016\/j.ymthe.2025.08.019","article-title":"Asparaginase enhances CAR-T cell antitumor immunity by asparagine metabolic reprogramming and central memory induction in ALL","volume":"33","author":"Zhu","year":"2025","journal-title":"Mol Ther"},{"issue":"771","key":"10.1016\/j.gendis.2026.102245_bib41","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.ado2084","article-title":"Engineering CAR-T therapies for autoimmune disease and beyond","volume":"16","author":"English","year":"2024","journal-title":"Sci Transl Med"},{"issue":"12","key":"10.1016\/j.gendis.2026.102245_bib42","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1200\/OP.22.00315","article-title":"Chimeric antigen receptor T-cell therapies: barriers and solutions to access","volume":"18","author":"Mikhael","year":"2022","journal-title":"JCO Oncol Pract"},{"issue":"7","key":"10.1016\/j.gendis.2026.102245_bib43","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1038\/s41375-018-0106-0","article-title":"Clinical use of lentiviral vectors","volume":"32","author":"Milone","year":"2018","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.gendis.2026.102245_bib44","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/s41408-021-00508-1","article-title":"AAV-mediated in vivo CAR gene therapy for targeting human T-cell leukemia","volume":"11","author":"Nawaz","year":"2021","journal-title":"Blood Cancer J"},{"issue":"2","key":"10.1016\/j.gendis.2026.102245_bib45","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.cell.2021.12.021","article-title":"Engineered virus-like particles for efficient in vivo delivery of therapeutic proteins","volume":"185","author":"Banskota","year":"2022","journal-title":"Cell"},{"issue":"11","key":"10.1016\/j.gendis.2026.102245_bib46","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.201809158","article-title":"In vivo generation of human CD19-CAR T cells results in b-cell depletion and signs of cytokine release syndrome","volume":"10","author":"Pfeiffer","year":"2018","journal-title":"EMBO Mol Med"},{"issue":"8","key":"10.1016\/j.gendis.2026.102245_bib47","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1016\/j.ymthe.2020.05.005","article-title":"In vivo generation of CAR T cells selectively in human CD4+ lymphocytes","volume":"28","author":"Agarwal","year":"2020","journal-title":"Mol Ther"},{"issue":"3","key":"10.1016\/j.gendis.2026.102245_bib48","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006292","article-title":"Preclinical proof of concept for VivoVec, a lentiviral-based platform for in vivo CAR T-cell engineering","volume":"11","author":"Michels","year":"2023","journal-title":"J Immunother Cancer"},{"issue":"9","key":"10.1016\/j.gendis.2026.102245_bib49","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1182\/blood.2024024523","article-title":"In vivo CAR T-cell generation in nonhuman primates using lentiviral vectors displaying a multidomain fusion ligand","volume":"144","author":"Nicolai","year":"2024","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.gendis.2026.102245_bib50","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/s41392-024-01780-w","article-title":"Adeno-associated virus as a delivery vector for gene therapy of human diseases","volume":"9","author":"Wang","year":"2024","journal-title":"Signal Transduct Target Ther"},{"issue":"6","key":"10.1016\/j.gendis.2026.102245_bib51","doi-asserted-by":"crossref","first-page":"283","DOI":"10.2217\/fvl-2017-0011","article-title":"Understanding capsid assembly and genome packaging for adeno-associated viruses","volume":"12","author":"Bennett","year":"2017","journal-title":"Future Virol"},{"issue":"2","key":"10.1016\/j.gendis.2026.102245_bib52","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1089\/hgtb.2012.243","article-title":"Pre-existing anti-adeno-associated virus antibodies as a challenge in AAV gene therapy","volume":"24","author":"Louis","year":"2013","journal-title":"Hum Gene Ther Methods"},{"issue":"9","key":"10.1016\/j.gendis.2026.102245_bib53","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.1172\/JCI35700","article-title":"Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1","volume":"118","author":"Hacein-Bey-Abina","year":"2008","journal-title":"J Clin Invest"},{"issue":"9","key":"10.1016\/j.gendis.2026.102245_bib54","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.3390\/v15091801","article-title":"Innate immune response to viral vectors in gene therapy","volume":"15","author":"Wang","year":"2023","journal-title":"Viruses"},{"issue":"21\u201322","key":"10.1016\/j.gendis.2026.102245_bib55","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1089\/hum.2022.090","article-title":"Regulatory consideration for the nonclinical safety assessment of gene therapies","volume":"33","author":"Moffit","year":"2022","journal-title":"Hum Gene Ther"},{"issue":"12","key":"10.1016\/j.gendis.2026.102245_bib56","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","article-title":"Lipid nanoparticles for mRNA delivery","volume":"6","author":"Hou","year":"2021","journal-title":"Nat Rev Mater"},{"issue":"3","key":"10.1016\/j.gendis.2026.102245_bib57","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1089\/nat.2018.0721","article-title":"Lipid nanoparticles enabling gene therapies: from concepts to clinical utility","volume":"28","author":"Kulkarni","year":"2018","journal-title":"Nucleic Acid Ther"},{"issue":"12","key":"10.1016\/j.gendis.2026.102245_bib58","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.3390\/pharmaceutics14122682","article-title":"Recent advances in lipid nanoparticles for delivery of mRNA","volume":"14","author":"Yang","year":"2022","journal-title":"Pharmaceutics"},{"issue":"6576","key":"10.1016\/j.gendis.2026.102245_bib59","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1126\/science.abm0594","article-title":"CAR T cells produced in vivo to treat cardiac injury","volume":"375","author":"Rurik","year":"2022","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.gendis.2026.102245_bib60","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1021\/acs.nanolett.9b04246","article-title":"Ionizable lipid nanoparticle-mediated mRNA delivery for human CAR T cell engineering","volume":"20","author":"Billingsley","year":"2020","journal-title":"Nano Lett"},{"issue":"7","key":"10.1016\/j.gendis.2026.102245_bib61","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-011759","article-title":"T cell-specific non-viral DNA delivery and in vivo CAR-T generation using targeted lipid nanoparticles","volume":"13","author":"Bimbo","year":"2025","journal-title":"J Immunother Cancer"},{"issue":"Pt 1","key":"10.1016\/j.gendis.2026.102245_bib62","article-title":"CAR-T cells generated in vivo for the targeted treatment of myocardial fibrosis","volume":"168","author":"Liu","year":"2026","journal-title":"Int Immunopharmacol"},{"issue":"4","key":"10.1016\/j.gendis.2026.102245_bib63","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/s41565-020-0669-6","article-title":"Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR-Cas gene editing","volume":"15","author":"Cheng","year":"2020","journal-title":"Nat Nanotechnol"},{"key":"10.1016\/j.gendis.2026.102245_bib64","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2021.121339","article-title":"In situ T-cell transfection by anti-CD3-conjugated lipid nanoparticles leads to T-cell activation, migration, and phenotypic shift","volume":"281","author":"Kheirolomoom","year":"2022","journal-title":"Biomaterials"},{"key":"10.1016\/j.gendis.2026.102245_bib65","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.trsl.2021.11.009","article-title":"Development of mRNA manufacturing for vaccines and therapeutics: mRNA platform requirements and development of a scalable production process to support early phase clinical trials","volume":"242","author":"Whitley","year":"2022","journal-title":"Transl Res"},{"issue":"5","key":"10.1016\/j.gendis.2026.102245_bib66","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1016\/j.ymthe.2022.02.001","article-title":"Lyophilization provides long-term stability for a lipid nanoparticle-formulated, nucleoside-modified mRNA vaccine","volume":"30","author":"Muramatsu","year":"2022","journal-title":"Mol Ther"},{"issue":"15","key":"10.1016\/j.gendis.2026.102245_bib67","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1056\/NEJMc2509522","article-title":"In vivo CD19 CAR T-cell therapy for refractory systemic lupus erythematosus","volume":"393","author":"Wang","year":"2025","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"10.1016\/j.gendis.2026.102245_bib68","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/hon.2595","article-title":"Managing the toxicities of CAR T-cell therapy","volume":"37","author":"Neelapu","year":"2019","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.gendis.2026.102245_bib69","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.omtm.2017.11.007","article-title":"Emerging issues in AAV-mediated in vivo gene therapy","volume":"8","author":"Colella","year":"2018","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"12","key":"10.1016\/j.gendis.2026.102245_bib70","doi-asserted-by":"crossref","first-page":"3485","DOI":"10.3324\/haematol.2023.282875","article-title":"CAR T-cell therapy for central nervous system lymphomas: blood and cerebrospinal fluid biology, and outcomes","volume":"108","author":"Lacan","year":"2023","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.gendis.2026.102245_bib71","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1172\/JCI97454","article-title":"Redirection to the bone marrow improves T cell persistence and antitumor functions","volume":"128","author":"Khan","year":"2018","journal-title":"J Clin Invest"},{"issue":"3","key":"10.1016\/j.gendis.2026.102245_bib72","article-title":"Harnessing the chemokine system to home CAR-T cells into solid tumors","volume":"3","author":"Foeng","year":"2022","journal-title":"Cell Rep Med"},{"issue":"44","key":"10.1016\/j.gendis.2026.102245_bib73","doi-asserted-by":"crossref","DOI":"10.1002\/anie.202310395","article-title":"Spleen SORT LNP generated in situ CAR T cells extend survival in a mouse model of lymphoreplete B cell lymphoma","volume":"62","author":"\u00c1lvarez-Benedicto","year":"2023","journal-title":"Angew Chem Int Ed Engl"},{"key":"10.1016\/j.gendis.2026.102245_bib74","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.jconrel.2024.04.022","article-title":"Lipid nanoparticle-based strategies for extrahepatic delivery of nucleic acid therapies\u2013challenges and opportunities","volume":"370","author":"Simonsen","year":"2024","journal-title":"J Control Release"},{"issue":"1","key":"10.1016\/j.gendis.2026.102245_bib75","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s40364-026-00905-3","article-title":"T-cell-targeted fusogenic nanovesicles generate CAR-T cells in vivo for rheumatoid arthritis therapy","volume":"14","author":"Liang","year":"2026","journal-title":"Biomark Res"},{"issue":"10","key":"10.1016\/j.gendis.2026.102245_bib76","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1038\/s41551-025-01511-8","article-title":"Targeting and tracking mRNA lipid nanoparticles at the particle, transcript and protein level","volume":"9","author":"Kang","year":"2025","journal-title":"Nat Biomed Eng"},{"issue":"11","key":"10.1016\/j.gendis.2026.102245_bib77","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1038\/s41587-023-02085-z","article-title":"In vivo human T cell engineering with enveloped delivery vehicles","volume":"42","author":"Hamilton","year":"2024","journal-title":"Nat Biotechnol"},{"issue":"5","key":"10.1016\/j.gendis.2026.102245_bib78","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gendis.2026.102245_bib79","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2024.1447147","article-title":"CAR-engineered T cell therapy as an emerging strategy for treating autoimmune diseases","volume":"11","author":"Vukovic","year":"2024","journal-title":"Front Med"},{"issue":"2","key":"10.1016\/j.gendis.2026.102245_bib80","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2023.2251839","article-title":"Chimeric antigen receptor T cell and regulatory T cell therapy in non-oncology diseases: a narrative review of studies from 2017 to 2023","volume":"19","author":"Sun","year":"2023","journal-title":"Hum Vaccin Immunother"},{"issue":"1","key":"10.1016\/j.gendis.2026.102245_bib81","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.1038\/s41467-018-05395-y","article-title":"The chimeric TAC receptor co-opts the T cell receptor yielding robust anti-tumor activity without toxicity","volume":"9","author":"Helsen","year":"2018","journal-title":"Nat Commun"},{"issue":"15","key":"10.1016\/j.gendis.2026.102245_bib82","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1016\/j.cell.2022.03.045","article-title":"Therapeutic in vivo delivery of gene editing agents","volume":"185","author":"Raguram","year":"2022","journal-title":"Cell"},{"issue":"24","key":"10.1016\/j.gendis.2026.102245_bib83","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.18.02079","article-title":"Cost effectiveness of chimeric antigen receptor T-cell therapy in multiply relapsed or refractory adult large B-cell lymphoma","volume":"37","author":"Lin","year":"2019","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.gendis.2026.102245_bib84","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","article-title":"Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus","volume":"28","author":"Mackensen","year":"2022","journal-title":"Nat Med"},{"issue":"7","key":"10.1016\/j.gendis.2026.102245_bib85","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/S1474-4422(23)00194-1","article-title":"Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b\/2a study","volume":"22","author":"Granit","year":"2023","journal-title":"Lancet Neurol"},{"issue":"10","key":"10.1016\/j.gendis.2026.102245_bib86","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1016\/j.ard.2025.06.2128","article-title":"BCMA-targeted CAR T cell therapy can effectively induce disease remission in refractory lupus nephritis","volume":"84","author":"Hu","year":"2025","journal-title":"Ann Rheum Dis"}],"container-title":["Genes & Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352304226002175?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352304226002175?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T15:51:04Z","timestamp":1792770664000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352304226002175"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2027,2]]},"references-count":86,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2027,2]]}},"alternative-id":["S2352304226002175"],"URL":"https:\/\/doi.org\/10.1016\/j.gendis.2026.102245","relation":{},"ISSN":["2352-3042"],"issn-type":[{"value":"2352-3042","type":"print"}],"subject":[],"published":{"date-parts":[[2027,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In vivo CAR-T for the treatment of autoimmune diseases: Current progress and future directions","name":"articletitle","label":"Article Title"},{"value":"Genes & Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gendis.2026.102245","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Publishing services by Elsevier B.V. on behalf of KeAi Communications Co. Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102245"}}